Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row
March 31, 2021
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders.
Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top private companies that are best positioned to capitalize on these trends to achieve growth. This selection methodology has been an accurate predictor of investment and business success with past “Ready to Rocket” companies.
“Each year when we choose the Ready to Rocket companies, we are looking for those companies that have achieved critical milestones along their commercialization roadmap. Sonic Incytes Medical Corp. is an excellent example of a company taking key steps toward achieving its commercial potential,” said Thealzel Lee, Senior Partner, Rocket Builders.
“It’s a great honour to be recognized by Rocket Builders for the second year in a row,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Fatty liver disease is an emerging health crisis that affects 1 in 4 people worldwide and, with FDA clearance of VelacurTM, we’re excited to offer health care practitioners a breakthrough, point of care ultrasound solution to address this problem.”
VelacurTM combines the principles of MRI with handheld ultrasound to quantify liver disease with greater accuracy and reliability than the current standard of care. VelacurTM is the first handheld 3D liver tissue assessment tool with accuracy comparable to MRI, paving the way for a non-invasive, low-cost and scalable solution to assess and manage millions of patients with liver disease.